On November 25, 2019, Asahi Kasei Pharma Denmark A / S ('Asahi Kasei Pharma Denmark') published a recommended conditional, voluntary public offer (the 'Offer') to purchase all issued and outstanding shares and warrants in Veloxis Pharmaceuticals A / S (OMX: VELO) ('Veloxis'), cf. Company Announcement No. 18/2019.

On January 9, 2020, Asahi Kasei Pharma Denmark announced that all relevant competition authorities have either approved the Offer and issued the necessary permits, or stated that they have no objection to the Offer, as contemplated in the Offer Document, cf. Company Announcement No. 1 / 2020. Since irrevocable acceptances have been received for more than 80% of the shares and warrants in Veloxis, the minimum condition for acceptance has also been fulfilled, cf. company announcement no.

The offer expires on January 14, 2020 at 17:00 (CET).

Veloxis 'Board of Directors wishes to reiterate its recommendation for the offer, as stated in the Board of Directors' statement of December 12, 2019: 'In the light of the analysis presented in this statement and having regard to the advantages and disadvantages of the Offer for Shareholders and Warrant Holders, The Board of Directors unanimously resolved to recommend the Shareholders and Warrant Holders to accept the Offer.

Contact:

Tel: +1 919-591-3090

Email: IR@Veloxis.com

About Veloxis

Veloxis is a specialized pharmaceutical company dedicated to improving the lives of transplant patients. As a Danish company, Veloxis operates in the United States through Veloxis Pharmaceuticals, Inc., a wholly owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR ( tacrolimus extended-release tablets ) based on the company's unique and patented delivery technology, MeltDose, designed to improve the absorption and bioavailability of selected orally administered pharmaceutical products. The company is focused on the immediate commercialization of Envarsus XR in the United States, the expansion of partnerships worldwide and the acquisition of assets used by transplanted patients and in adjacent medical specialty areas. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

Disclaimer

The offer is not made directly or indirectly in any jurisdiction where this would be contrary to the law of that jurisdiction. This Notice and other documents relating to the Offer shall not be sent, forwarded or distributed in any way in any jurisdiction if this would constitute a violation of the law of that jurisdiction, including in particular Canada, Japan, Australia or South Africa. This announcement does not constitute an offer or invitation to sell or buy Veloxis shares. The Offer is made solely in the form of the Offer Document, prepared and published by Asahi Kasei Pharma Denmark, which contains the complete terms and conditions of the Offer. Veloxis shareholders and warrant holders are encouraged to read the offer document,

The Offer is made in the United States in accordance with Section 14 (e) of and Regulation 14E issued pursuant to the United States Securities Exchange Act of 1934, as amended (the Exchange Act), as regards the offer to purchase outstanding shares subject to the exceptions in Rule 14d-1 of the Exchange Act and otherwise in accordance with Danish law. In accordance with one or more exceptions provided for in Rule 14e-5 (b) of the Exchange Act, Asahi Kasei Pharma Denmark or its representatives or brokers (acting as agents or the like for Asahi Kasei Pharma Denmark) may at any time acquire or enter into agreements on to be able to acquire Veloxis shares and warrants outside the United States otherwise than under the Offer during the period during which the Offer is open for acceptance.

(C) 2020 Electronic News Publishing, source ENP Newswire